Therapeutic | Tarextumab |
Target | NOTCH2&3 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSVIASSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSIFYTTWGQGTLVTVSS |
Light Chain | DIVLTQSPATLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNFPITFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | MorphoSys HuCAL Phage Display;XmAb Engineering Technology |
INN Year Proposed | 2013 |
INN Year Recommended | 2014 |
Companies Involved | OncoMed Pharmaceuticals |
Conditions Approved | na |
Conditions Active | Pancreatic cancer, Small cell lung cancer |
Conditions Discontinued | Solid tumours |
Notes |